Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2261
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction ; volume:22 ; number:1 ; day:13 ; month:5 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cardiovascular disorders ; 22, Heft 1 (13.5.2022), 1-8, 12.2022
- Creator
-
Bolla, Giovanni Battista
Fedele, Antonella
Faggiano, Andrea
Sala, Carla
Santangelo, Gloria
Carugo, Stefano
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12872-022-02647-0
- URN
-
urn:nbn:de:101:1-2022071822035672665534
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bolla, Giovanni Battista
- Fedele, Antonella
- Faggiano, Andrea
- Sala, Carla
- Santangelo, Gloria
- Carugo, Stefano
- SpringerLink (Online service)
Other Objects (12)
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina